Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma

Table 3

Univariate and multivariate analyses (Cox regression model) of 341 EC.

	Univariate analysis			Multivariate analysis
	HR	OS 95% CI	value	HR	OS 95% CI	value
Histological type (type 1 vs. 2)	14.837	6.805, 32.350	<0.001	9.935	2.683, 36.790	<0.001
Clinical staging (FIGO I, II vs. III, IV)	13.327	5.856, 30.330	<0.001	8.283	2.993, 22.925	<0.001
Tumor grading (grade 1, 2 vs. 3, high)	7.333	3.445, 15.606	<0.001
Positive lymph nodes (yes vs. no)	8.24	3.882, 17.490	<0.001
LVSI (yes vs. no)	6.539	3.088, 13.847	<0.001	2.62	1.043, 6.581	0.040
MI (yes vs. no)	10.36	3.937, 27.259	<0.001	3.771	1.271, 11.188	0.017
Vimentin	0.243	0.116, 0.512	<0.001

EC: endometrial carcinoma; FIGO: Federation International of Gynecology and Obstetrics Association; LVSI: lymph vascular space invasion; MI: myometrium invasion.